Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- Check2 days agoChange DetectedThe Ukraine location entry in the Locations list was updated to use a different transliteration (Zaporizhzhya) from Zaporizhzhia. The old entry was removed and a new one added.SummaryDifference0.0%

- Check9 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, signaling a newer version of the study detail page. This is a metadata change rather than a substantive update to the study content.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, signaling a minor update to the content or metadata on the study details page.SummaryDifference0.0%

- Check37 days agoChange Detected- Revision updated from v3.6.0 to v3.6.2 on the page, signaling a new release/version behind the scenes. This does not appear to change the visible study details or user-facing content.SummaryDifference0.0%

- Check53 days agoChange DetectedRecruitment status updated to 'No longer looking for participants'; the page's intervention labeling and related headers were updated (Intervention/Treatment added and Intervention / Treatment removed) as part of Revision v3.6.0.SummaryDifference0.1%

- Check60 days agoChange DetectedKharkiv Oblast location was added with the city Kharkiv, Kharkiv Oblast, Ukraine, 61070. The previous Kharkivs’ka Oblast’ entry (Kharkiv, Kharkivs’ka Oblast’, Ukraine, 61070) was removed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.